Cover Image for Nakanoshima Qross Global Life Sciences Cluster: NQ Global Life Science Startup & Investment Connect vol.5
Cover Image for Nakanoshima Qross Global Life Sciences Cluster: NQ Global Life Science Startup & Investment Connect vol.5
Avatar for CIC Japan Events
Presented by
CIC Japan Events
CIC Japan Events

Nakanoshima Qross Global Life Sciences Cluster: NQ Global Life Science Startup & Investment Connect vol.5

Virtual
Registration
Welcome! To join the event, please register below.
About Event

​Nakanoshima Qross Global Life Sciences Cluster

​​NQ Global Life Science Startup & Investment Connect vol.5

​*Japanese follows.

​A Special Program Connecting Global Startups, Investment Communities, and Business Opportunities

​Building on the growing interest and opportunities for exchange generated by Expo 2025 Osaka, Kansai, this program aims to transform these connections from a one-time opportunity into continuous collaboration.

​Through Nakanoshima Qross, we seek to foster an international life science innovation ecosystem and investment community that connects startups, investors, corporations, research institutions, and global innovation hubs.

​The program will feature three events. In addition to introducing activities and initiatives by overseas life science clusters, promising Japanese startups will deliver pitches designed to facilitate new business matching and international collaboration among investors, corporations, and startups.

​

​Event 1 - Global Ecosystem

​【Event Details】

  • ​Date & Time : Tuesday, November 24, 2026, 6:30-6:50pm JST

  • ​Format : Online

  • ​Language : English (*Some announcements may be provided in Japanese.)

  • ​Speakers : WILCO

  • ​Who Should Attend :

    • ​Life science and healthcare startups

    • ​VCs, CVCs, investors, and corporate investors

    • ​Companies in pharmaceuticals, medical devices, diagnostics, regenerative medicine, biomanufacturing, and digital health

    • ​Universities, research institutions, and healthcare organizations

    • ​Overseas life science clusters, accelerators, and support organizations

    • ​Companies and organizations interested in collaboration with startups, investment, joint research, business development, and international expansion

  • ​Organizer : Osaka Prefecture

  • ​Program Office : Organization of Future Medicine

  • ​Operational Partner : CIC Japan Innovation Services G.K.

  • ​Supporting Partner : Osaka Life Science Nexus by Nippon Life and CIC

​

​Event 2 - Startup Pitch : Biotechnology & Drug Discovery

​【Event Details】

  • ​Date & Time : Tuesday, November 24, 2026, 6:50-9:20 JST

  • ​Format : Online

  • ​Language : English (*Some announcements may be provided in Japanese.)

  • ​Speakers :

    1. ​Yo (Max)Amakusa, MBA / CEO of iBody Inc.

    2. ​Ayan Sengupta / CEO of Myimmune Corporation

    3. ​TBA

  • ​Who Should Attend :

    • ​Life science and healthcare startups

    • ​VCs, CVCs, investors, and corporate investors

    • ​Companies in pharmaceuticals, medical devices, diagnostics, regenerative medicine, biomanufacturing, and digital health

    • ​Universities, research institutions, and healthcare organizations

    • ​Overseas life science clusters, accelerators, and support organizations

    • ​Companies and organizations interested in collaboration with startups, investment, joint research, business development, and international expansion

  • ​Organizer : Osaka Prefecture

  • ​Program Office : Organization of Future Medicine

  • ​Operational Partner : CIC Japan Innovation Services G.K.

  • ​Supporting Partner : Osaka Life Science Nexus by Nippon Life and CIC

​

​Event 3 - Startup Pitch : Medical Devices & Digital Health

​【Event Details】

  • ​Date & Time : Tuesday, November 24, 2026, 6:50-9:20 JST

  • ​Format : Online

  • ​Language : English (*Some announcements may be provided in Japanese.)
    We're currently accepting applications from startups to present at the pitch event! Click here to apply.

  • ​Speakers:

    1. ​Masaya Miyazaki, Ph.D. / Founder & CEO of HaKaL inc.

    2. ​Aoi Sasaki / Global Expansion Lead of Quadlytics Inc.

    3. ​Hidenori Nakamura, MBA / Founder & CEO of atDose Co., Ltd.

    4. ​TBA

  • ​Who Should Attend :

    • ​Life science and healthcare startups

    • ​VCs, CVCs, investors, and corporate investors

    • ​Companies in pharmaceuticals, medical devices, diagnostics, regenerative medicine, biomanufacturing, and digital health

    • ​Universities, research institutions, and healthcare organizations

    • ​Overseas life science clusters, accelerators, and support organizations

    • ​Companies and organizations interested in collaboration with startups, investment, joint research, business development, and international expansion

  • ​Organizer : Osaka Prefecture

  • ​Program Office : Organization of Future Medicine

  • ​Operational Partner : CIC Japan Innovation Services G.K.

  • ​Supporting Partner : Osaka Life Science Nexus by Nippon Life and CIC

​【Speakers' Detail】

​<Event 2 - Startup Pitch : Biotechnology & Drug Discovery>

​1. Yo (Max)Amakusa, MBA / CEO of iBody Inc.

​Yo (Max) Amakusa is the CEO of iBody Inc., a biotechnology startup originating from Nagoya University, Japan. He has approximately 20 years of experience in the pharmaceutical and biotechnology industries, with a background in sales, marketing, business development, and strategic partnerships.
  Before becoming CEO of iBody in March 2020, he held positions at Sumitomo Pharma, IQVIA, and a biotechnology venture, gaining extensive experience in pharmaceutical commercialization and business development.
  At iBody, he leads corporate strategy, international business development, and strategic collaborations with pharmaceutical and diagnostic companies. Under his leadership, the company has expanded its business beyond Japan, actively building partnerships across the United States, Europe, and Asia.
  He is passionate about translating innovative academic research into practical solutions that address unmet needs in healthcare and life sciences. He holds an MBA from Bond-BBT Global Leadership MBA Program.

​iBody Inc. is a biotechnology company originating from Nagoya University, Japan. Its proprietary antibody discovery technology enables rapid and comprehensive discovery of highly functional antibodies that are difficult to obtain using conventional methods.
  Leveraging the high affinity and specificity of rabbit-derived antibodies, iBody addresses diverse needs in pharmaceutical and diagnostic development, including challenging targets such as small molecules, GPCRs, and phosphorylated proteins.
  The company provides contract research services and conducts collaborative research with pharmaceutical and diagnostic companies in Japan and internationally.
  Recently, iBody launched a joint project with PATH, a US-based international nonprofit organization, further accelerating its global business expansion.

​2. Ayan Sengupta / CEO of Myimmune Corporation

​Ayan Sengupta is co-founder and Chief Executive Officer of MyImmune Corporation, where he leads the development of the company’s AbSapien Platform, which is an AI platform for discovering fully human antibodies. He has about seven years of experience in artificial intelligence and machine learning. He began in research on automated negotiation models, work that produced peer-reviewed papers and patents, and then moved into natural language processing of English and Japanese documents and large language models. He later shifted to engineering and AI product development, building machine learning systems for production use. For the past two years he has applied this experience to immunology in collaboration with Professor Daron Standley of The University of Osaka, working on immune repertoire-based diagnostics, prediction of treatment response, and antibody discovery. That collaboration became MyImmune.

​MyImmune Corporation is an AI drug discovery company that finds fully human antibodies for therapeutic development. Its AbSapien Platform searches two billion natural human antibody sequences, drawn from the B cell receptor repertoires of human donors, to identify antibodies that recognize a chosen target. Because every candidate has already been produced by a human immune system, the platform is designed to reduce the immunogenicity and developability risks that come with antibodies from animal immunization or synthetic libraries. A search takes minutes, and it is supported by MyImmune’s own machine learning models for epitope prediction, affinity, and heavy and light chain pairing. Candidates identified by AbSapien have been expressed and confirmed to bind their targets in laboratory assays. The technology builds on patents licensed from the University of Osaka and on more than a decade of research in computational immunology by the founding team. MyImmune is a spin-out of Osaka University and is a member of the OIST Innovation Accelerator. The company partners with pharmaceutical and biotechnology companies on antibody discovery programs.

​

​<Event 3 - Startup Pitch : Medical Devices & Digital Health>

​1. Masaya Miyazaki, Ph.D. / Founder & CEO of HaKaL inc.

​Masaya Miyazaki is the Founder and CEO of HaKaL Inc., a Japanese startup developing portable diagnostic technologies, and a Visiting Professor at the Graduate School of Systems Life Sciences, Kyushu University.
  He received his PhD in Science from Saga University in 1995 and subsequently conducted postdoctoral research at the Joslin Diabetes Center, Harvard Medical School, under Professor Steven E. Shoelson. He later joined the National Institute of Advanced Industrial Science and Technology (AIST) in Japan, where he led research teams developing microfluidic technologies, miniaturized analytical systems, and innovative biochemical assays.
  In 2020, he founded HaKaL to translate these technologies into practical diagnostic solutions for use outside conventional laboratories.
  With extensive experience in analytical biochemistry, microfluidics, and diagnostic device development, he is now leading the commercialization of HaKaL's portable diagnostic platform for animal health and human infectious diseases. His current focus includes building international research and commercial partnerships to expand access to rapid, reliable testing in diverse healthcare and field settings.

​HaKaL Inc. is a Japanese deep tech startup developing a portable diagnostic platform that enables rapid, sensitive testing directly at the point of need.
  Building on microfluidic technologies and advanced biochemical assays developed through Japanese universities and research institutions, HaKaL combines a palm sized, battery powered optical reader with disposable diagnostic cartridges. The platform delivers results within 15 to 30 minutes and connects with smartphones and cloud systems for data management and monitoring.
  Our initial commercialization efforts focus on livestock health in Japan, including rapid screening for bovine leukemia virus. We are also expanding our technology to human infectious diseases, including dengue, Zika, and other diseases where timely access to laboratory testing remains challenging.
  Unlike conventional diagnostic solutions designed for specific diseases, our modular platform can be adapted to multiple biomarkers, sample types, and testing environments.
  HaKaL is seeking international partnerships with diagnostic companies, healthcare providers, and research institutions to accelerate product development, clinical validation, manufacturing, and market entry, including opportunities for collaboration in Europe.

​

​2. Aoi Sasaki / Global Expansion Lead of Quadlytics Inc.

​Aoi Sasaki is the Global Expansion Lead at Quadlytics Inc., a Japanese MedTech startup developing a SaMD to support people living with epilepsy. Originally from Sapporo, she studied neuroscience at the University of Melbourne and joined Quadlytics as a graduate in 2026. She works on building relationships with healthcare and research institutions and business partners, as well as exploring market entry strategies in Australia, the United States, the United Kingdom and beyond. Aoi is passionate about bringing technology that supports people living with epilepsy and their families to communities around the world.

​We are a Kyoto-based startup originating from Kyoto University, Nagoya University, and Kumamoto University. We are developing a medical device that uses wearable ECG and proprietary AI to detect pre-ictal signs and alert patients and caregivers before a seizure occurs. Our technology provides advance awareness of seizure risk, helping enable timely responses in daily life. By combining clinical insights with advanced data analytics, we aim to address unmet needs in epilepsy care. Through continued collaboration with academic and medical institutions, we are advancing clinical development and working towards bringing our solution to people living with epilepsy in Australia, the United States, the United Kingdom, and beyond.

​

​3. Hidenori Nakamura, MBA / Founder & CEO of atDose Co., Ltd.

​I have experience in mold design, system development, project management, marketing, and IT consulting.
  In March 2013, I completed the Master of Business Administration (MBA) at Toyo University’s Graduate School of Business Administration.
  From September 2013 to June 2017, I worked at Deloitte, where I was engaged in financial auditing, management consulting, and venture support. In September 2017, I founded atDose Co., Ltd.

​Guided by the vision of delivering the right amount of medicine only to the affected area with consistent precision, atDose develops ultra-small, localized drug-delivery devices using its proprietary electro-osmotic pump (EO pump). The compact, moving-part-free pump delivers and aspirates microliter-scale volumes at a constant rate, even through fine needles and highly viscous fluids. Its first ophthalmic device is in the final stage of launch preparation, with planned expansion to subretinal, inner-ear, and brain delivery for gene therapies and regenerative medicine products. The company operates from Japan and India, where it established a local subsidiary in 2022.

​

​============================

​

​Nakanoshima Qross Global Life Sciences Cluster

​​NQ Global Life Science Startup & Investment Connect vol.5

​2025年大阪・関西万博を契機に高まった国内外からの関心や交流の機会を、一過性のものではなく継続的な共創へと発展させることを目指し、Nakanoshima Qrossを核とした国際的なライフサイエンス・イノベーションエコシステムおよび投資コミュニティの形成を推進します。

​当日は、3つのイベントを開催します。海外のライフサイエンス・クラスターによる活動紹介に加え、国内有望スタートアップによるピッチを実施し、投資家・事業会社・スタートアップをつなぐ新たなビジネスマッチングと国際連携の創出を促進します。

​

​Event 1 - Global Ecosystem

​【開催概要】

  • ​日時:2026年11月24日(火)6:30-6:50pm JST

  • ​形態:オンライン

  • ​言語:英語 (*一部日本語での案内がございます。)

  • ​登壇社:WILCO

  • ​参加対象:

    • ​ライフサイエンス・ヘルスケア領域のスタートアップ

    • ​VC、CVC、事業会社、投資家

    • ​製薬、医療機器、診断、再生医療、バイオ製造、デジタルヘルス関連企業

    • ​大学、研究機関、医療機関

    • ​海外クラスター、アクセラレーター、支援機関

    • ​スタートアップとの協業、投資、共同研究、事業開発、海外展開に関心のある企業・団体

  • ​主催:大阪府

  • ​運営事務局:一般財団法人未来医療推進機構

  • ​運営協力:CIC Japan Innovation Services 合同会社

  • ​協力:Osaka Life Science Nexus by Nippon Life and CIC

​

​Event 2 - Startup Pitch : バイオテクノロジー・創薬

​【開催概要】

  • ​日時:2026年11月24日(火)6:50-7:20pm JST

  • ​形態:オンライン

  • ​言語:英語 (*一部日本語での案内がございます。)

  • ​登壇者:

    1. ​天草 陽 氏 / iBody株式会社 代表取締役CEO

    2. ​セングプタ アヤン 氏 / Myimmune Corporation CEO

    3. ​TBA

  • ​参加対象:

    • ​ライフサイエンス・ヘルスケア領域のスタートアップ

    • ​VC、CVC、事業会社、投資家

    • ​製薬、医療機器、診断、再生医療、バイオ製造、デジタルヘルス関連企業

    • ​大学、研究機関、医療機関

    • ​海外クラスター、アクセラレーター、支援機関

    • ​スタートアップとの協業、投資、共同研究、事業開発、海外展開に関心のある企業・団体

  • ​主催:大阪府

  • ​運営事務局:一般財団法人未来医療推進機構

  • ​運営協力:CIC Japan Innovation Services 合同会社

  • ​協力:Osaka Life Science Nexus by Nippon Life and CIC

​Event 3 - Startup Pitch : 医療機器・デジタルヘルス

​ピッチ登壇スタートアップ募集中!
登壇お申し込みはこちら

  • ​日時:2026年11月24日(火)7:20-7:50pm JST

  • ​形態:オンライン

  • ​言語:英語 (*一部日本語での案内がございます。)

  • ​登壇者:

    1. ​宮崎 真佐也 氏 / 株式会社HaKaL 代表取締役

    2. ​佐々木 葵彩 氏 / クアドリティクス株式会社 グローバル展開リード

    3. ​中村 秀剛 氏 / アットドウス株式会社 代表取締役

    4. ​TBA

  • ​参加対象:

    • ​ライフサイエンス・ヘルスケア領域のスタートアップ

    • ​VC、CVC、事業会社、投資家

    • ​製薬、医療機器、診断、再生医療、バイオ製造、デジタルヘルス関連企業

    • ​大学、研究機関、医療機関

    • ​海外クラスター、アクセラレーター、支援機関

    • ​スタートアップとの協業、投資、共同研究、事業開発、海外展開に関心のある企業・団体

  • ​主催:大阪府

  • ​運営事務局:一般財団法人未来医療推進機構

  • ​運営協力:CIC Japan Innovation Services 合同会社

  • ​協力:Osaka Life Science Nexus by Nippon Life and CIC

​【登壇者詳細】

​<Event 2 - Startup Pitch : バイオテクノロジー・創薬>

​1. 天草 陽 氏 / iBody株式会社 代表取締役CEO

​製薬業界で約20年にわたり、営業、マーケティング、事業開発に従事。住友ファーマ、IQVIA、バイオベンチャーでの経験を経て、2020年3月にiBody株式会社の代表取締役CEOに就任。名古屋大学発の独自抗体ディスカバリー技術を基盤に、製薬・診断薬企業との共同研究や事業提携を推進。日本国内に加え、米国・欧州・アジアでの事業展開を積極的に進め、研究成果の社会実装とグローバル市場への展開に取り組んでいる。Bond-BBT MBA取得。

​iBody株式会社は、名古屋大学発のバイオテクノロジー企業です。独自の抗体ディスカバリー技術により、従来技術では取得が困難だった高機能抗体を迅速かつ網羅的に探索します。ウサギ由来抗体の高い親和性・特異性を強みとし、医薬品・診断薬開発の多様なニーズに対応。国内外の製薬・診断薬企業への受託研究や共同研究を展開。米国の国際的な非営利組織PATHとの共同プロジェクトにも取り組み、グローバル展開を加速しています。

​

​2. セングプタ アヤン 氏 / Myimmune Corporation CEO

​アヤンセングプタは、MyImmune Corporationの共同創業者兼最高経営責任者(CEO)であり、完全ヒト抗体を探索するAIプラットフォーム「AbSapien Platform」の開発を率いている。人工知能・機械学習の分野で約7年の経験を持つ。自動交渉モデルの研究からキャリアを始め、査読付き論文と特許の成果を上げた後、英語および日本語文書の自然言語処理と大規模言語モデルに取り組んだ。その後、エンジニアリングとAIプロダクト開発に軸足を移し、実運用向けの機械学習システムを構築してきた。過去2年間は、大阪大学のダロン・スタンドレー教授と共同でこの経験を免疫学に応用し、免疫レパートリーに基づく診断、治療応答の予測、抗体探索に取り組んでいる。この共同研究がMyImmuneの設立につながった。

​MyImmune Corporationは、治療薬開発に向けた完全ヒト抗体を探索するAI創薬企業です。同社のAbSapien Platformは、ヒトドナーのB細胞受容体レパートリーに由来する20億件の天然ヒト抗体配列を検索し、目的の標的を認識する抗体を特定します。すべての候補はヒトの免疫系によってすでに産生された抗体であるため、動物免疫や合成ライブラリー由来の抗体に伴う免疫原性および開発可能性のリスクを低減できるよう設計されています。検索は数分で完了し、エピトープ予測、親和性、重鎖・軽鎖ペアリングに関するMyImmune独自の機械学習モデルがこれを支えています。AbSapienで特定された候補抗体は実際に発現され、標的への結合が実験で確認されています。本技術は、大阪大学からライセンスを受けた特許と、創業チームによる10年以上にわたる計算免疫学の研究に基づいています。MyImmuneは大阪大学発のスピンアウト企業であり、OIST Innovation Acceleratorのメンバーです。同社は製薬企業およびバイオテクノロジー企業と抗体探索プログラムで提携しています。

​

​<Event 3 - Startup Pitch : 医療機器・デジタルヘルス>

​1. 宮崎 真佐也 氏 / 株式会社HaKaL 代表取締役

​株式会社HaKaL代表取締役、九州大学大学院客員教授。佐賀大学で博士(理学)を取得後、米国Harvard Medical SchoolのJoslin Diabetes Centerで博士研究員として研究に従事。産業技術総合研究所で約15年間、マイクロ流体技術や小型分析システムの研究開発を主導。2020年にHaKaLを創業し、独自の分析技術を活用した現場迅速診断システムの事業化と国際展開を推進している。

​株式会社HaKaLは、大学・研究機関発のマイクロ流体技術と高感度分析技術を基盤に、現場で使える迅速診断プラットフォームを開発するスタートアップです。小型・電池駆動の測定装置と使い捨て検査キットを組み合わせ、15〜30分で検査結果を提供します。日本では家畜感染症の診断から事業化を進め、デング熱などのヒト感染症にも展開しています。スマートフォンやクラウドとの連携により、世界各地での診断アクセス向上を目指しています。

​

​2. 佐々木 葵彩 氏 / クアドリティクス株式会社 グローバル展開リード

​札幌市出身。豪・メルボルン大学にて神経科学を専攻し、2026年にクアドリティクス株式会社へグローバル展開リードとして新卒入社。豪州・米国・英国をはじめとする市場で、医療・研究機関や事業パートナーとの連携構築、市場参入に向けた情報収集と戦略検討に取り組む。てんかん患者さんとそのご家族の暮らしを支える技術を、世界へ届けることを目指している。

​当社は、京都大学・名古屋大学・熊本大学発の医療機器スタートアップです。ウェアラブル心電計と独自のAIを用いて、てんかん発作の兆候を最長20分前に検知し、患者やケアギバーに警告するシステムを開発しています。発作への備えを支援することで、患者さんとご家族が安心して暮らせる社会を目指しています。基礎的な技術開発を終え、国内外の医療・研究機関と連携しながら臨床開発と海外展開を進めています。

​

​3. 中村 秀剛 氏 / アットドウス株式会社 代表取締役

​金型設計、システム開発・プロジェクトマネジメント・マーケティング、ITコンサルティングを経て、2013年3月 東洋大学大学院経営学専攻修士課程修了(MBA)、中小企業診断士登録。2013年9月〜2017年6月 監査法人トーマツ/トーマツベンチャーサポートにて会計監査、経営コンサルティング、ベンチャー支援に従事。2017年9月 アットドウス株式会社を設立し代表取締役に就任。

​「薬を、患部にだけ、必要な量だけ、誰が使っても同じ精度で」を理念に、独自の電気浸透流ポンプ(EOポンプ)を用いた超微量・局所投与デバイスを開発する医療機器メーカーです。可動部のない約4cmの小型ポンプで、極細針や高粘性薬液でもμL単位を一定速度で投与・吸引できます。第一号の眼科用デバイスは上市準備中で、今後は網膜下・内耳・脳内への遺伝子治療・再生医療向けへ展開。2022年設立のインド法人とともに日印二拠点で事業化を進めています。

Avatar for CIC Japan Events
Presented by
CIC Japan Events
CIC Japan Events